What is Lyfegen?
Lyfegen operates as an independent provider of sophisticated rebate management software, catering to the intricate needs of the healthcare sector. Its solutions are instrumental for health insurances, governments, hospital payers, and pharmaceutical companies worldwide, aiming to streamline the administration of complex drug pricing agreements and enhance rebate optimization for better value realization. The company boasts the world's largest digital repository of innovative drug pricing models and public agreements, complemented by a robust drug pricing simulator that allows for dynamic scenario modeling to assess the full financial implications of various pricing strategies. Founded in 2018 and headquartered in Basel, Switzerland, Lyfegen has established a notable market presence across Europe, North America, and the Middle East.
How much funding has Lyfegen raised?
Lyfegen has raised a total of $13.6M across 2 funding rounds:
Series A
$8M
Series A
$5.6M
Series A (2022): $8M with participation from aMoon and APEX Ventures
Series A (2024): $5.6M led by aMoon and TX Ventures
Key Investors in Lyfegen
aMoon
aMoon is a healthcare investment firm that partners with exceptional scientists and entrepreneurs to build companies focused on transforming healthcare through technology and biology. They invest in early and late-stage companies that pursue disruptive solutions for high unmet medical needs, leveraging their global network to enhance execution capabilities.
APEX Ventures
APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies. The firm is run by founders with complementary backgrounds and a shared mission to support startups with disruptive technology.
TX Ventures
Undisclosed investor participating in the funding round.
What's next for Lyfegen?
With its recent major strategic investment, Lyfegen is poised for accelerated growth and market expansion. The substantial enterprise-level funding indicates a strong investor confidence in the company's technology and its capacity to address critical inefficiencies within the healthcare supply chain. This capital infusion will likely fuel further development of its rebate management platform, enhance its drug pricing simulation capabilities, and support its global outreach efforts. Lyfegen's strategic focus on optimizing drug pricing and rebate processes positions it as a key player in driving financial efficiency and transparency within the pharmaceutical and healthcare payer ecosystems.
See full Lyfegen company page
